These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39315463)

  • 1. Trends of bone mineral density and bone quality in a paediatric kidney transplant recipient: A case report.
    Aoyagi J; Kanai T; Ito T; Saito T; Betsui H; Kurosaki M; Maru T; Ono M; Tajima T
    Nephrology (Carlton); 2024 Sep; ():. PubMed ID: 39315463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid effects on bone strength in children with renal diseases.
    Aoyagi J; Kanai T; Ito T; Odaka J; Saito T; Betsui H; Kurosaki M; Maru T; Yamagata T
    Nephrology (Carlton); 2021 Feb; 26(2):119-125. PubMed ID: 33207023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial.
    Mawatari T; Ikemura S; Matsui G; Iguchi T; Mitsuyasu H; Kawahara S; Maehara M; Muraoka R; Iwamoto Y; Nakashima Y
    Bone Rep; 2020 Jun; 12():100275. PubMed ID: 32462056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study exploring useful indicators for low bone mineral density in male alcoholic patients.
    Horai T; Hishimoto A; Otsuka I; So T; Mouri K; Shimmyo N; Boku S; Okishio N; Sora I
    Neuropsychiatr Dis Treat; 2018; 14():663-669. PubMed ID: 29535522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tartrate-Resistant Acid Phosphatase 5b in Young Patients With Sickle Cell Disease and Trait Siblings: Relation to Vasculopathy and Bone Mineral Density.
    Mokhtar GM; Tantawy AA; Hamed AA; Adly AA; Ismail EA; Makkeyah SM
    Clin Appl Thromb Hemost; 2017 Jan; 23(1):64-71. PubMed ID: 26149452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
    Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
    Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C.
    Ichikawa T; Yamashima M; Yamamichi S; Koike M; Nakano Y; Honda T; Yajima H; Miyazaki O; Kuribayashi Y; Ikeda T; Okamura T; Nakao K
    Biomed Rep; 2022 Nov; 17(5):84. PubMed ID: 36185786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia.
    Ota I; Ota Y; Ota K; Eda H; Ohta H
    JBMR Plus; 2022 Nov; 6(11):e10690. PubMed ID: 36398113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
    Kasai H; Mori Y; Ose A; Shiraki M; Tanigawara Y
    J Clin Pharmacol; 2021 May; 61(5):606-613. PubMed ID: 33135182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
    Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
    Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
    Hori M; Yasuda K; Takahashi H; Kondo C; Shirasawa Y; Ishimaru Y; Sekiya Y; Morozumi K; Maruyama S
    Sci Rep; 2022 May; 12(1):7781. PubMed ID: 35546172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone turnover in passive smoking female rat: relationships to change in bone mineral density.
    Gao SG; Li KH; Xu M; Jiang W; Shen H; Luo W; Xu WS; Tian J; Lei GH
    BMC Musculoskelet Disord; 2011 Jun; 12():131. PubMed ID: 21663694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment.
    Nakamura Y; Suzuki T; Kato H
    Ther Clin Risk Manag; 2017; 13():1343-1348. PubMed ID: 29062234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undercarboxylated Osteocalcin and Its Associations With Bone Mineral Density, Bone Turnover Markers, and Prevalence of Osteopenia and Osteoporosis in Chinese Population: A Cross-Sectional Study.
    Xu Y; Shen L; Liu L; Zhang Z; Hu W
    Front Endocrinol (Lausanne); 2022; 13():843912. PubMed ID: 35898467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients.
    Cao Y; Liu X; Xu H
    Clin Lab; 2012; 58(7-8):845-50. PubMed ID: 22997989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.
    Kurosawa S; Doki N; Senoo Y; Kishida Y; Nagata A; Yamada Y; Konishi T; Kaito S; Yoshifuji K; Matsuyama N; Shirane S; Uchida T; Inamoto K; Toya T; Igarashi A; Najima Y; Muto H; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Ann Hematol; 2020 Aug; 99(8):1873-1882. PubMed ID: 32451708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in bone turnover markers after discontinuing long-term glucocorticoid administration in children with idiopathic nephrotic syndrome: a multicenter retrospective observational study.
    Ueda Y; Okamoto T; Sato Y; Hayashi A; Takahashi T; Suzuki R; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T; Manabe A
    Pediatr Nephrol; 2023 Oct; 38(10):3285-3296. PubMed ID: 37052692
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.